Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD …

Speakers include world-renowned physicians

Meeting to begin at 8:00 am ET; webcast will be available

/EIN News/ — DEVON, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical Research Day on December 15, 2016, from 8:00 am to 10:30 am ET in New York City. The focus for the meeting will be the potential role that ZYN002 CBD gel may play in providing relief for patients with debilitating conditions including epilepsy, osteoarthritis and Fragile X syndrome.

In addition to members of Zynerba’s executive management team, the following key opinion leaders will participate in the Clinical Research Day: